# OnCo record nct05317858 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05317858/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05317858", "NCT05317858" ;
  schema:name "Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets"@en ;
  schema:alternateName "LIMITLESS"@en ;
  schema:description "A phase 3 trial of Pembrolizumab, Atezolizumab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by InSightec, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05317858/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05317858> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-08-12" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/insightec/> .